Proteostasis Therapeutics Inc. plans to sell 9 million common shares in an underwritten public offering
The company plans to grant the underwriters an option to buy up to an additional 15%, or 1,350,000 common shares, in the public offering.
Leerink Partners and RBC Capital Markets are acting as joint book-running managers, and H.C. Wainwright & Co. is acting as lead manager for the offering.